Get the Stockscreener App
107.76
1.01%
-1.10
Axsome Therapeutics Inc stock is traded at $107.76, with a volume of 413.07K.
It is down -1.01% in the last 24 hours and up +5.99% over the past month.
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products includes AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.
See More
Previous Close:
$108.86
Open:
$108.86
24h Volume:
413.07K
Relative Volume:
0.50
Market Cap:
$5.52B
Revenue:
$338.46M
Net Income/Loss:
$-310.96M
P/E Ratio:
-16.50
EPS:
-6.53
Net Cash Flow:
$-132.82M
1W Performance:
-3.97%
1M Performance:
+5.99%
6M Performance:
+19.64%
1Y Performance:
+46.25%
1-Day Range:
$107.66
$110.16
1-Week Range:
$107.66
$120.00
52-Week Range:
$64.11
$139.13
Axsome Therapeutics Inc Stock (AXSM) Company Profile
Name
Axsome Therapeutics Inc
Sector
Industry
Phone
(212) 332-3241
Address
ONE WORLD TRADE CENTER, 29TH FLOOR, NEW YORK
Compare AXSM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AXSM
Axsome Therapeutics Inc
|
107.76 | 5.52B | 338.46M | -310.96M | -132.82M | -6.53 |
|
VRTX
Vertex Pharmaceuticals Inc
|
424.99 | 128.84B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
527.78 | 65.38B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
549.65 | 39.67B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
251.15 | 33.82B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
231.99 | 27.60B | 3.81B | -644.79M | -669.77M | -6.24 |
Axsome Therapeutics Inc Stock (AXSM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-07-25 | Initiated | Jefferies | Buy |
| Feb-11-25 | Initiated | Deutsche Bank | Buy |
| Dec-31-24 | Reiterated | Mizuho | Outperform |
| Sep-03-24 | Initiated | Wells Fargo | Overweight |
| Aug-06-24 | Upgrade | BofA Securities | Neutral → Buy |
| Jul-22-24 | Initiated | Needham | Buy |
| Apr-29-24 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Mar-19-24 | Initiated | Robert W. Baird | Outperform |
| Feb-06-24 | Initiated | UBS | Buy |
| Jan-25-24 | Initiated | RBC Capital Mkts | Outperform |
| Dec-13-23 | Initiated | Citigroup | Buy |
| Aug-08-23 | Upgrade | BofA Securities | Underperform → Neutral |
| Jan-05-23 | Initiated | Piper Sandler | Neutral |
| Nov-01-22 | Initiated | Loop Capital | Buy |
| Sep-07-22 | Resumed | Mizuho | Buy |
| Aug-10-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jun-10-21 | Initiated | Berenberg | Buy |
| Jan-08-21 | Initiated | Jefferies | Buy |
| Dec-16-20 | Initiated | Mizuho | Buy |
| Sep-29-20 | Initiated | BofA Securities | Underperform |
| Sep-10-20 | Initiated | Morgan Stanley | Overweight |
| Apr-28-20 | Reiterated | H.C. Wainwright | Buy |
| Apr-14-20 | Initiated | Cowen | Outperform |
| Dec-30-19 | Reiterated | H.C. Wainwright | Buy |
| Dec-17-19 | Reiterated | H.C. Wainwright | Buy |
| Dec-16-19 | Reiterated | Guggenheim | Buy |
| Oct-16-19 | Initiated | Guggenheim | Buy |
| Sep-18-19 | Initiated | William Blair | Outperform |
| May-28-19 | Initiated | SunTrust | Buy |
| May-23-19 | Reiterated | H.C. Wainwright | Buy |
| Apr-08-19 | Initiated | SVB Leerink | Outperform |
| Mar-15-19 | Reiterated | H.C. Wainwright | Buy |
| Oct-03-16 | Resumed | Brean Capital | Buy |
| Dec-15-15 | Initiated | Cantor Fitzgerald | Buy |
| Dec-14-15 | Initiated | Ladenburg Thalmann | Buy |
View All
Axsome Therapeutics Inc Stock (AXSM) Latest News
Cubist Systematic Strategies LLC Purchases New Position in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Axsome Therapeutics (NASDAQ:AXSM) Stock Price Up 5.6% Following Strong Earnings - MarketBeat
Axsome Therapeutics (NASDAQ:AXSM) Posts Quarterly Earnings Results, Beats Expectations By $0.46 EPS - MarketBeat
FY2025 EPS Estimates for AXSM Lifted by Cantor Fitzgerald - MarketBeat
Axsome Therapeutics (NASDAQ:AXSM) Issues Earnings Results - MarketBeat
Schonfeld Strategic Advisors LLC Has $2.15 Million Position in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Axsome Therapeutics (NASDAQ:AXSM) Price Target Cut to $180.00 by Analysts at HC Wainwright - MarketBeat
FY2028 Earnings Forecast for AXSM Issued By William Blair - MarketBeat
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Shares Purchased by Price T Rowe Associates Inc. MD - MarketBeat
Axsome Therapeutics, Inc. Sued for Securities Law Violations; Investors Should Contact Block & Leviton for More Information - ACCESS Newswire
Alethea Capital Management LLC Has $62.13 Million Holdings in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Short Interest Down 14.2% in April - MarketBeat
Axsome targets FDA decision on AXS-14 for fibromyalgia in Q2 2025 - MSN
Robert W. Baird Forecasts Strong Price Appreciation for Axsome Therapeutics (NASDAQ:AXSM) Stock - MarketBeat
Brevan Howard Capital Management LP Acquires 24,393 Shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Analysts Are Updating Their Axsome Therapeutics, Inc. (NASDAQ:AXSM) Estimates After Its First-Quarter Results - Yahoo Finance
AXSM Q1 Loss Narrower Than Expected, Auvelity Drives Revenues Y/Y - MSN
Axsome Therapeutics at Citizens JMP Life Sciences: Strategic Growth Unveiled - Investing.com India
Bridgefront Capital LLC Buys Shares of 10,555 Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Shares Acquired by Tower Research Capital LLC TRC - MarketBeat
Ally Bridge Group NY LLC Purchases New Stake in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Boxer Capital Management LLC Makes New $39.77 Million Investment in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Axsome Therapeutics Q1: Marketing-Driven Growth Masks Profitability Concerns (AXSM) - Seeking Alpha
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Holdings Lifted by First Trust Advisors LP - MarketBeat
Baird Raises Price Target for Axsome Therapeutics (AXSM) | AXSM Stock News - GuruFocus
Bellevue Group AG Sells 248,251 Shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Q1 2025 Earnings Call Transcript - Insider Monkey
Axsome Therapeutics (AXSM) Target Price Boosted Post Q1 Update | - GuruFocus
Axsome Therapeutics (AXSM) Price Target Increased Amid Positive Outlook | AXSM Stock News - GuruFocus
Axsome Therapeutics (AXSM) Target Price Boosted Post Q1 Update | AXSM Stock News - GuruFocus
Deutsche Bank Adjusts Axsome Therapeutics Price Target to $190 From $187, Maintains Buy Rating - marketscreener.com
Avidity Partners Management LP Cuts Stake in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
BVF Inc. IL Grows Stake in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Wells Fargo Increases Price Target for Axsome Therapeutics (AXSM) Amid Growth Prospects | AXSM Stock News - GuruFocus
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Stock Holdings Cut by PDT Partners LLC - MarketBeat
Axsome Therapeutics Inc (AXSM) Q1 2025 Earnings Call Highlights: Robust Revenue Growth and ... By GuruFocus - Investing.com Canada
Axsome Therapeutics Reports Strong Q1 2025 Growth - TipRanks
Axsome Therapeutics (AXSM) Reports Strong Q1 Growth and Strategi - GuruFocus
Decoding Axsome Therapeutics Inc (AXSM): A Strategic SWOT Insigh - GuruFocus
Axsome: Q1 Earnings Snapshot - MySA
Axsome Therapeutics (AXSM) Sees Stock Rise Following Earnings Re - GuruFocus
Earnings call transcript: Axsome Therapeutics beats EPS forecast in Q1 2025 - Investing.com Nigeria
Axsome Therapeutics’ Earnings Call Highlights Growth and Challenges - TipRanks
Axsome Therapeutics Inc (AXSM) Q1 2025 Earnings: EPS of $(1.22) - GuruFocus
Axsome Therapeutics (AXSM) Reports Strong Q1 Revenue and Advance - GuruFocus
Axsome Therapeutics (AXSM) Beats Q1 Expectations with Robust Rev - GuruFocus
Axsome Therapeutics Q1 2025 Earnings Preview - MSN
Axsome Therapeutics, Inc. SEC 10-Q Report - TradingView
Voya Investment Management LLC Boosts Stock Position in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Axsome Therapeutics Inc earnings beat by $0.08, revenue fell short of estimates - Investing.com Nigeria
Axsome Therapeutics Q1 2025 Earnings Call Transcript - MarketBeat
Axsome Therapeutics Inc Stock (AXSM) Financials Data
Revenue
Net Income
Cash Flow
EPS
Axsome Therapeutics Inc Stock (AXSM) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Pizzie Nick | Chief Financial Officer |
Feb 14 '25 |
Option Exercise |
3.50 |
3,000 |
10,500 |
45,187 |
| Pizzie Nick | Chief Financial Officer |
Feb 13 '25 |
Sale |
129.86 |
12,000 |
1,558,320 |
42,187 |
| Pizzie Nick | Chief Financial Officer |
Feb 14 '25 |
Sale |
131.07 |
3,000 |
393,210 |
42,187 |
0.84%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):